NCT03017378View on ClinicalTrials.gov

Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

February 28, 2015

Conditions
Tuberculosis
Interventions
BIOLOGICAL

TB/FLU-01L

TB / FLU-01L (intranasal application)

BIOLOGICAL

TB/FLU-01L

TB/FLU-01L (sublingual application)

Trial Locations (1)

050000

National Center for Tuberculosis Problems, Kazakhstan, Almaty Qalasy

All Listed Sponsors
collaborator

Ministry of Health, Kazakhstan

OTHER_GOV

collaborator

Research Institute of Influenza, Russia

OTHER

lead

Research Institute for Biological Safety Problems

OTHER_GOV

NCT03017378 - Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine | Biotech Hunter | Biotech Hunter